Eli Lilly said the FDA is expected to decide on its oral obesity candidate orforglipron in Q2 2026 after granting a national-priority fast review, positioning the pill to follow injectables into the market. Lilly expects rapid evaluation and plans to deploy online cash-pay channels and Medicare access to accelerate uptake. Separately, the FDA notified companies that suicide-related warnings will be removed from GLP-1 obesity drug labels after a post-market assessment found no elevated risk. Regulators’ actions reduce safety overhang and clear a path for broader adoption and payer conversations for obesity medicines.